- Home
- VIP vs IGC Comparison
VIP vs IGC Comparison
Compare VIP & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VIP | IGC |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.7M | 32.0M |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | VIP | IGC |
|---|---|---|
| Price | $1.89 | $0.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.25 |
| AVG Volume (30 Days) | 175.4K | ★ 1.0M |
| Earning Date | N/A | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.09 | 59.09 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $70,388,000.00 | $1,271,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.55 | $0.24 |
| 52 Week High | $2.74 | $0.45 |
Technical Indicators
Market Signals| Indicator | VIP | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 41.71 | 54.79 |
| Support Level | $1.72 | $0.28 |
| Resistance Level | $1.95 | $0.31 |
| Average True Range (ATR) | 0.12 | 0.02 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 66.07 | 41.12 |
Price Performance
Historical ComparisonAbout VIP Vulcan Infrastructure and Power Inc. Class A Common Stock
Vulcan Infrastructure and Power Inc is a power and infrastructure platform focused on acquiring, developing and operating energized sites that support artificial intelligence and high-performance computing data centers, as well as local electricity grids.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.